HomeBUSINESS
BUSINESS

Takeda Launches PI Study of Zika Vaccine Candidate
(Nov.30.2017)

Takeda Pharmaceutical said on November 29 that it has initiated a PI clinical study of its investigational Zika vaccine candidate TAK-426. The study is designed to evaluate the safety and immunogenicity of the vaccine at multiple dose levels in 240 subjects aged between 18 and 49 in the US ...
(LOG IN FOR FULL STORY)